This report provides a comprehensive analysis of the global antisense oligonucleotide (ASO) drugs market for treating transthyretin amyloidosis (ATTR), a condition characterized by misfolded protein accumulation. It examines market dynamics, key growth drivers, and technological advancements through 2032, covering segments such as Inotersen and Eplontersen across various applications. The study offers detailed regional insights for the Americas, APAC, and Europe, while evaluating the competitive landscape and strategic positioning of major players like Ionis Pharmaceuticals and AstraZeneca.

Market Overview

The global Antisense Oligonucleotides Drugs for ATTR market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate over the forecast period.

Technology Overview

Antisense oligonucleotide (ASO) drugs represent a groundbreaking approach for treating transthyretin amyloidosis (ATTR), a condition characterized by the accumulation of misfolded transthyretin proteins that lead to organ damage. These ASO drugs work by targeting and degrading the mRNA that encodes for transthyretin, thus reducing its production at the source.

Regional Market Analysis

United States

The United States market for Antisense Oligonucleotides Drugs for ATTR is estimated to increase from 2025 through 2032, maintaining a consistent compound annual growth rate.

China

The China market for Antisense Oligonucleotides Drugs for ATTR is estimated to increase from 2025 through 2032, maintaining a consistent compound annual growth rate.

Europe

The Europe market for Antisense Oligonucleotides Drugs for ATTR is estimated to increase from 2025 through 2032, maintaining a consistent compound annual growth rate.

Market Segmentation

By Type

• Inotersen
• Eplontersen
• Other

By Application

• Hospital and Clinic
• Retail Pharmacies
• Other

By Geography

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key Players

The profiled companies have been selected based on inputs gathered from primary experts and an analysis of the company's coverage, product portfolio, and market penetration. Key players include:

• Akcea Therapeutics
• AstraZeneca
• Ionis Pharmaceuticals

Market Share and Dynamics

In terms of revenue, the global two largest companies occupied a significant portion of the market share in 2025. The report highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Furthermore, the report analyzes the strategies of leading global companies with a focus on:

• Antisense Oligonucleotides Drugs for ATTR portfolios and capabilities
• Market entry strategies
• Market positions
• Geographic footprints

Research Methodology and Scope

LP Information, Inc. (LPI)'s newest research report, the “Antisense Oligonucleotides Drugs for ATTR Industry Forecast,” reviews total world Antisense Oligonucleotides Drugs for ATTR sales in 2025. It provides a comprehensive analysis by region and market sector of projected Antisense Oligonucleotides Drugs for ATTR sales for 2026 through 2032.

With sales broken down by region, market sector, and sub-sector, this report provides a detailed analysis in US$ millions of the world Antisense Oligonucleotides Drugs for ATTR industry. The study evaluates key market trends, drivers, and affecting factors shaping the global outlook, breaking down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity. The forecast utilizes a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs to offer a nuanced view of the current state and future trajectory of the market.

Key Questions Addressed

• What is the 10-year outlook for the global Antisense Oligonucleotides Drugs for ATTR market?
• What factors are driving Antisense Oligonucleotides Drugs for ATTR market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Antisense Oligonucleotides Drugs for ATTR market opportunities vary by end market size?
• How does Antisense Oligonucleotides Drugs for ATTR break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Antisense Oligonucleotides Drugs for ATTR Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Antisense Oligonucleotides Drugs for ATTR by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Antisense Oligonucleotides Drugs for ATTR by Country/Region, 2021, 2025 & 2032

  • 2.2 Antisense Oligonucleotides Drugs for ATTR Segment by Type

    • 2.2.1 Inotersen

    • 2.2.2 Eplontersen

    • 2.2.3 Other

    • 2.2.4 Antisense Oligonucleotides Drugs for ATTR Sales by Type

      • 2.2.4.1 Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Type (2021-2026)
      • 2.2.4.2 Global Antisense Oligonucleotides Drugs for ATTR Revenue and Market Share by Type (2021-2026)
      • 2.2.4.3 Global Antisense Oligonucleotides Drugs for ATTR Sale Price by Type (2021-2026)

  • 2.3 Antisense Oligonucleotides Drugs for ATTR Segment by Application

    • 2.3.1 Hospital and Clinic

    • 2.3.2 Retail Pharmacies

    • 2.3.3 Other

    • 2.3.4 Antisense Oligonucleotides Drugs for ATTR Sales by Application

      • 2.3.4.1 Global Antisense Oligonucleotides Drugs for ATTR Sale Market Share by Application (2021-2026)
      • 2.3.4.2 Global Antisense Oligonucleotides Drugs for ATTR Revenue and Market Share by Application (2021-2026)
      • 2.3.4.3 Global Antisense Oligonucleotides Drugs for ATTR Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Antisense Oligonucleotides Drugs for ATTR Breakdown Data by Company

    • 3.1.1 Global Antisense Oligonucleotides Drugs for ATTR Annual Sales by Company (2021-2026)

    • 3.1.2 Global Antisense Oligonucleotides Drugs for ATTR Sales Market Share by Company (2021-2026)

  • 3.2 Global Antisense Oligonucleotides Drugs for ATTR Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Antisense Oligonucleotides Drugs for ATTR Revenue by Company (2021-2026)

    • 3.2.2 Global Antisense Oligonucleotides Drugs for ATTR Revenue Market Share by Company (2021-2026)

  • 3.3 Global Antisense Oligonucleotides Drugs for ATTR Sale Price by Company

  • 3.4 Key Manufacturers Antisense Oligonucleotides Drugs for ATTR Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Antisense Oligonucleotides Drugs for ATTR Product Location Distribution

    • 3.4.2 Players Antisense Oligonucleotides Drugs for ATTR Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Antisense Oligonucleotides Drugs for ATTR by Geographic Region

  • 4.1 World Historic Antisense Oligonucleotides Drugs for ATTR Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Antisense Oligonucleotides Drugs for ATTR Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Antisense Oligonucleotides Drugs for ATTR Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Antisense Oligonucleotides Drugs for ATTR Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Antisense Oligonucleotides Drugs for ATTR Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Antisense Oligonucleotides Drugs for ATTR Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Antisense Oligonucleotides Drugs for ATTR Sales Growth

  • 4.4 APAC Antisense Oligonucleotides Drugs for ATTR Sales Growth

  • 4.5 Europe Antisense Oligonucleotides Drugs for ATTR Sales Growth

  • 4.6 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales Growth

• 5 Americas

  • 5.1 Americas Antisense Oligonucleotides Drugs for ATTR Sales by Country

    • 5.1.1 Americas Antisense Oligonucleotides Drugs for ATTR Sales by Country (2021-2026)

    • 5.1.2 Americas Antisense Oligonucleotides Drugs for ATTR Revenue by Country (2021-2026)

  • 5.2 Americas Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026)

  • 5.3 Americas Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Antisense Oligonucleotides Drugs for ATTR Sales by Region

    • 6.1.1 APAC Antisense Oligonucleotides Drugs for ATTR Sales by Region (2021-2026)

    • 6.1.2 APAC Antisense Oligonucleotides Drugs for ATTR Revenue by Region (2021-2026)

  • 6.2 APAC Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026)

  • 6.3 APAC Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Antisense Oligonucleotides Drugs for ATTR by Country

    • 7.1.1 Europe Antisense Oligonucleotides Drugs for ATTR Sales by Country (2021-2026)

    • 7.1.2 Europe Antisense Oligonucleotides Drugs for ATTR Revenue by Country (2021-2026)

  • 7.2 Europe Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026)

  • 7.3 Europe Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR by Country

    • 8.1.1 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Antisense Oligonucleotides Drugs for ATTR Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Antisense Oligonucleotides Drugs for ATTR

  • 10.3 Manufacturing Process Analysis of Antisense Oligonucleotides Drugs for ATTR

  • 10.4 Industry Chain Structure of Antisense Oligonucleotides Drugs for ATTR

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Antisense Oligonucleotides Drugs for ATTR Distributors

  • 11.3 Antisense Oligonucleotides Drugs for ATTR Customer

• 12 World Forecast Review for Antisense Oligonucleotides Drugs for ATTR by Geographic Region

  • 12.1 Global Antisense Oligonucleotides Drugs for ATTR Market Size Forecast by Region

    • 12.1.1 Global Antisense Oligonucleotides Drugs for ATTR Forecast by Region (2027-2032)

    • 12.1.2 Global Antisense Oligonucleotides Drugs for ATTR Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Antisense Oligonucleotides Drugs for ATTR Forecast by Type (2027-2032)

  • 12.7 Global Antisense Oligonucleotides Drugs for ATTR Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Akcea Therapeutics

    • 13.1.1 Akcea Therapeutics Company Information

    • 13.1.2 Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Product Portfolios and Specifications

    • 13.1.3 Akcea Therapeutics Antisense Oligonucleotides Drugs for ATTR Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Akcea Therapeutics Main Business Overview

    • 13.1.5 Akcea Therapeutics Latest Developments

  • 13.2 AstraZeneca

    • 13.2.1 AstraZeneca Company Information

    • 13.2.2 AstraZeneca Antisense Oligonucleotides Drugs for ATTR Product Portfolios and Specifications

    • 13.2.3 AstraZeneca Antisense Oligonucleotides Drugs for ATTR Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 AstraZeneca Main Business Overview

    • 13.2.5 AstraZeneca Latest Developments

  • 13.3 Ionis Pharmaceuticals

    • 13.3.1 Ionis Pharmaceuticals Company Information

    • 13.3.2 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Product Portfolios and Specifications

    • 13.3.3 Ionis Pharmaceuticals Antisense Oligonucleotides Drugs for ATTR Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Ionis Pharmaceuticals Main Business Overview

    • 13.3.5 Ionis Pharmaceuticals Latest Developments

• 14 Research Findings and Conclusion